Stock ALNFL NFL BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

All News NFL Biosciences

Equities

ALNFL

FR0014003XT0

Market Closed - Euronext Paris
Other stock markets
 16:35:14 17/05/2024 BST 		5-day change 1st Jan Change
2.18 EUR +1.40% Intraday chart for NFL Biosciences +6.34% +51.39%
04-12 Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
04-12 NFL Biosciences: successful capital increase CF

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NFL Biosciences : Assemblée générale mixte du 30 mai 2024
PU
NFL Biosciences : further strengthens its operational team with the arrival of a Head of Development and Manufacturing
PU
NFL Biosciences : renforce son équipe opérationnelle avec l’arrivée d’une Responsable du développement et de la fabrication
PU
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...
Our Logo
NFL Biosciences: successful capital increase
CF
NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships
MT
NFL Biosciences : Successful capital increase for NFL Biosciences with over €3 million raised
PU
NFL Biosciences : launches a fundraising round for 3 million euros through a capital increase
PU
NFL Biosciences : lance une levée de fonds d’environ 3 millions d’euros par voie d’augmentations de capital
PU
NFL BIOSCIENCES : SHOWCASES THE RESULTS OF ITS STUDIES TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITIES
PU
NFL BIOSCIENCES : VALORISE SES RÉSULTATS D’ÉTUDES AUPRÈS DE LA COMMUNAUTÉ SCIENTIFIQUE ET PHARMACEUTIQUE
PU
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS ANNUELS 2023
PU
NFL BIOSCIENCES: 2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE
PU
NFL BIOSCIENCES: INITIATION OF ANALYST COVERAGE BY PORTZAMPARC - BNP PARIBAS GROUP
PU
NFL Biosciences: success of smoking cessation study
CF
NFL Biosciences : PRE-IND application filed with the FDA in the United States for NFL-301, indicated for reducing alcohol consumption
PU
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNIS POUR NFL- 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL
PU
NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FOR NFL-301, INDICATED FOR REDUCING ALCOHOL CONSUMPTION
PU
NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE
PU
NFL Biosciences : Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALNFL Stock
  4. News NFL Biosciences